f Nimotuzumab in Advanced Cervical Cancer: Safety and Efficacy Profile


Lorente RR, Alfonso S, Sanchez Y, Viada C, Ortiz R, Ortiz CEVR, Troche M, et al. (2019) Nimotuzumab in Advanced Cervical Cancer: Safety and Efficacy Profile. Int J Oncol Res 2:016. doi.org/10.23937/2643-4563/1710016


© 2019 Lorente RR, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

REVIEW ARTICLE |  OPEN ACCESS DOI: 10.23937/2643-4563/1710016

Nimotuzumab in Advanced Cervical Cancer: Safety and Efficacy Profile

Raiza Ruiz Lorente, Sayly Alfonso, Yamilka Sanchez, Carmen Elena Viada, Ramón Ortiz, Mayelin Troche, Meylan Cepeda, Ana Rosa Vals, Leticia Cabrera, Annia Gorte, Delmis Maira Batista, Milagros Domenech, Jessica Garcia Viamontes, Conrado Ramos Mico and Mayra Ramos Suzarte*

Center of Molecular Immunology, Atabey, Havana, Cuba


The EGF receptor is over expressed in tumors of epithelial origin and is associated with a poor prognosis of the disease. An Expanded Clinical Access Program was carried out, in which patients with cervical uterine cancer in advanced stages of the disease without another therapeutic alternative were treated with nimotuzumab, anti-epidermal growth factor receptor humanized monoclonal antibody to evaluate the safety and efficacy of this therapy. Seventy-five patients with confirmed histological diagnosis of advanced cervical cancer were included, with previous onco-specific treatments (surgery, radiotherapy or radiochemotherapy), with ECOG at the inclusion ≤ 3 and life expectancy of more than three months. The mAb was administered in two stages: The induction stage with weekly administration, once a week in a dose of 200 mg intravenously; for twelve weeks and the second or maintenance stage with the same dose but every 14 days, until unmanageable toxicity or the decision of the patients. The therapy was well tolerated with an acceptable safety profile, not exceeding 2% the severe adverse events related to nimotuzumab treatment. The median overall survival exceeded the expectation by arriving at 23.5 months. We suggest follow up to a clinical trial in more early stage of the disease to combine nimotuzumab with chemo-radiotherapy.